Amedeo Smart

Free Medical Literature Service


 

Amedeo

Malignant Melanoma

  Free Subscription

Articles published in
PLoS One
    January 2024
  1. PEISEN F, Gerken A, Dahm I, Nikolaou K, et al
    Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy.
    PLoS One. 2024;19:e0296253.
    >> Share

  2. WIES C, Schneider L, Haggenmuller S, Bucher TC, et al
    Evaluating deep learning-based melanoma classification using immunohistochemistry and routine histology: A three center study.
    PLoS One. 2024;19:e0297146.
    >> Share

  3. LIU Y, Wang S, Wei S, Qiu X, et al
    The promotive role of lncRNA MIR205HG in proliferation, invasion, and migration of melanoma cells via the JMJD2C/ALKBH5 axis.
    PLoS One. 2024;19:e0290986.
    >> Share

  4. SHIRALKAR J, Anthony T, McCallum GA, Durand DM, et al
    Neural recordings can differentiate between spontaneously metastasizing melanomas and melanomas with low metastatic potential.
    PLoS One. 2024;19:e0297281.
    >> Share

  5. VON MONTFORT C, Aplak E, Ebbert L, Wenzel CK, et al
    The role of GAPDH in the selective toxicity of CNP in melanoma cells.
    PLoS One. 2024;19:e0300718.
    >> Share

  6. NAEEM A, Anees T
    DVFNet: A deep feature fusion-based model for the multiclassification of skin cancer utilizing dermoscopy images.
    PLoS One. 2024;19:e0297667.
    >> Share

    January 2023
  7. ZHOU S, Yamada R, Sakamoto K
    Low energy multiple blue light-emitting diode light Irradiation promotes melanin synthesis and induces DNA damage in B16F10 melanoma cells.
    PLoS One. 2023;18:e0281062.
    >> Share

  8. VOGEL RI, Luo X, Brown K, Jewett P, et al
    A UVR-sensor wearable device intervention to reduce sun exposure in melanoma survivors: Results from a randomized controlled trial.
    PLoS One. 2023;18:e0281480.
    >> Share

  9. SORENSEN AL, Guldmann-Christensen M, Borgesen M, Petersen RK, et al
    Detection of BRAF mutations in malignant melanoma and colorectal cancer by SensiScreen(R) FFPE BRAF qPCR assay.
    PLoS One. 2023;18:e0281558.
    >> Share

  10. KRANKE T, Tripolt-Droschl K, Rod L, Hofmann-Wellenhof R, et al
    New AI-algorithms on smartphones to detect skin cancer in a clinical setting-A validation study.
    PLoS One. 2023;18:e0280670.
    >> Share

  11. ALI A, Madni A, Shah H, Jamshaid T, et al
    Solid lipid-based nanoparticulate system for sustained release and enhanced in-vitro cytotoxic effect of 5-fluorouracil on skin Melanoma and squamous cell carcinoma.
    PLoS One. 2023;18:e0281004.
    >> Share

  12. SHAO H, Teramae D, Wells A
    Axl contributes to efficient migration and invasion of melanoma cells.
    PLoS One. 2023;18:e0283749.
    >> Share


  13. Retraction: Long non-coding RNA FTH1P3 facilitates uveal melanoma cell growth and invasion through miR-224-5p.
    PLoS One. 2023;18:e0282986.
    >> Share

  14. ORLOW I, Sadeghi KD, Edmiston SN, Kenney JM, et al
    InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma.
    PLoS One. 2023;18:e0269324.
    >> Share

  15. TAJERIAN A, Kazemian M, Tajerian M, Akhavan Malayeri A, et al
    Design and validation of a new machine-learning-based diagnostic tool for the differentiation of dermatoscopic skin cancer images.
    PLoS One. 2023;18:e0284437.
    >> Share

  16. PANG JM, Chien PC, Kao MC, Chiu PY, et al
    MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.
    PLoS One. 2023;18:e0284744.
    >> Share

  17. TABATABAI MA, Bahri N, Matthews-Juarez P, Alcendor D, et al
    The role of histological subtypes in the survival of patients diagnosed with cutaneous or mucosal melanoma in the United States of America.
    PLoS One. 2023;18:e0286538.
    >> Share

  18. ZHU H, Zhang P, Shi J, Kou D, et al
    Exosome-delivered circRPS5 inhibits the progression of melanoma via regulating the miR-151a/NPTX1 axis.
    PLoS One. 2023;18:e0287347.
    >> Share

  19. DIVINCENZO MJ, Angell CD, Suarez-Kelly LP, Ren C, et al
    Expression of microRNAs and their target genes in melanomas originating from gynecologic sites.
    PLoS One. 2023;18:e0285804.
    >> Share

  20. MA W, Wu Z, Maghsoudloo M, Ijaz I, et al
    Dermokine mutations contribute to epithelial-mesenchymal transition and advanced melanoma through ERK/MAPK pathways.
    PLoS One. 2023;18:e0285806.
    >> Share

  21. KUHN CK, Meister J, Kreft S, Stiller M, et al
    TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities.
    PLoS One. 2023;18:e0281487.
    >> Share

  22. CLEVENGER LM, Wrenn JD, Bena J, Sodhi G, et al
    Clustering of uveal melanoma: County wide analysis within Ohio.
    PLoS One. 2023;18:e0290284.
    >> Share

  23. HOCK BD, Goddard L, MacPherson SA, Strother M, et al
    Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab.
    PLoS One. 2023;18:e0290793.
    >> Share

  24. MAEKAWA N, Konnai S, Hosoya K, Kim S, et al
    Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
    PLoS One. 2023;18:e0291727.
    >> Share

  25. CHAN LH, Wang P, Abuhammad S, Lim LRJ, et al
    PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanoma.
    PLoS One. 2023;18:e0292278.
    >> Share


  26. Retraction: Enhancing radiosensitivity of melanoma cells through very high dose rate pulses released by a plasma focus device.
    PLoS One. 2023;18:e0294549.
    >> Share

  27. BONERT M, Berzins A, Begum H, Schittenhelm J, et al
    Neuroanatomical location of brain metastases from solid tumours based on pathology: An analysis of 511 patients with a comparison to the provided clinical history.
    PLoS One. 2023;18:e0294154.
    >> Share

  28. SOARES PRO, Passos DCS, da Silva FM, da Silva-Giardini APB, et al
    In vitro antiproliferative and apoptotic effects of thiosemicarbazones based on (-)-camphene and R-(+)-limonene in human melanoma cells.
    PLoS One. 2023;18:e0295012.
    >> Share

  29. DUNLOP KLA, Keogh LA, Smith AL, Aranda S, et al
    Acceptability and appropriateness of a risk-tailored organised melanoma screening program: Qualitative interviews with key informants.
    PLoS One. 2023;18:e0287591.
    >> Share

  30. KHAN S, Khan A
    SkinViT: A transformer based method for Melanoma and Nonmelanoma classification.
    PLoS One. 2023;18:e0295151.
    >> Share

    January 2022
  31. FIDALGO F, Torrezan GT, Sa BCS, Barros BDF, et al
    Family-based whole-exome sequencing identifies rare variants potentially related to cutaneous melanoma predisposition in Brazilian melanoma-prone families.
    PLoS One. 2022;17:e0262419.
    >> Share

  32. MCKAY DR, Nguyen P, Wang A, Hanna TP, et al
    A population-based study of administrative data linkage to measure melanoma surgical and pathology quality.
    PLoS One. 2022;17:e0263713.
    >> Share

  33. SHI X, Zhou Q, Huang B, Xia S, et al
    Prognostic and immune-related value of STK17B in skin cutaneous melanoma.
    PLoS One. 2022;17:e0263311.
    >> Share

  34. CASTRO RPR, Casagrande Tavoloni Braga J, Petaccia de Macedo M, Lopes Pinto CA, et al
    Hotspot analysis by confocal microscopy can help to differentiate challenging melanocytic skin lesions.
    PLoS One. 2022;17:e0263819.
    >> Share

  35. LECOUTURIER J, Bosomworth H, Labus M, Ellis RA, et al
    Health professional and patient views of a novel prognostic test for melanoma: A theoretically informed qualitative study.
    PLoS One. 2022;17:e0265048.
    >> Share


  36. Retraction: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells.
    PLoS One. 2022;17:e0268357.
    >> Share


  37. Retraction: Bcl-2 Regulates HIF-1alpha Protein Stabilization in Hypoxic Melanoma Cells via the Molecular Chaperone HSP90.
    PLoS One. 2022;17:e0268235.
    >> Share

  38. GENISH I, Gabay B, Ruban A, Goldshmit Y, et al
    Electroporation-based proteome sampling ex vivo enables the detection of brain melanoma protein signatures in a location proximate to visible tumor margins.
    PLoS One. 2022;17:e0265866.
    >> Share

  39. PECONI J, O'Neill C, Fegan G, Lanyon K, et al
    Sunproofed study protocol: A mixed-methods scoping study of sun safety policies in primary schools in Wales.
    PLoS One. 2022;17:e0268141.
    >> Share

  40. MONTAHA S, Azam S, Rafid AKMRH, Islam S, et al
    A shallow deep learning approach to classify skin cancer using down-scaling method to minimize time and space complexity.
    PLoS One. 2022;17:e0269826.
    >> Share

  41. SCHAEFER H, Rubben A, Esser A, Araujo A, et al
    A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with dabrafenib and trametinib evidenced by an algorithm-defined pyrexia score.
    PLoS One. 2022;17:e0273478.
    >> Share


  42. Retraction: MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression.
    PLoS One. 2022;17:e0274144.
    >> Share

  43. REIGSTAD A, Herdlevaer CF, Rigg E, Hoang T, et al
    CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells.
    PLoS One. 2022;17:e0273711.
    >> Share

  44. DENG H, Chen Y, Wang J, An R, et al
    HLA-DRB1: A new potential prognostic factor and therapeutic target of cutaneous melanoma and an indicator of tumor microenvironment remodeling.
    PLoS One. 2022;17:e0274897.
    >> Share

  45. HEERFORDT IM, Andersen JD, Philipsen PA, Langhans L, et al
    Detection of cutaneous malignant melanoma using RNA sampled by tape strips: A study protocol.
    PLoS One. 2022;17:e0274413.
    >> Share

  46. BURAI S, Kovacs R, Molnar T, Toth M, et al
    Comprehensive analysis of different tumor cell-line produced soluble mediators on the differentiation and functional properties of monocyte-derived dendritic cells.
    PLoS One. 2022;17:e0274056.
    >> Share

  47. XU J, Ma H, Shan B
    Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis.
    PLoS One. 2022;17:e0273163.
    >> Share

  48. REHMAN M, Ali M, Obayya M, Asghar J, et al
    Machine learning based skin lesion segmentation method with novel borders and hair removal techniques.
    PLoS One. 2022;17:e0275781.
    >> Share

  49. SIEWE N, Friedman A
    Optimal timing of steroid initiation in response to CTLA-4 antibody in metastatic cancer: A mathematical model.
    PLoS One. 2022;17:e0277248.
    >> Share

  50. PRATT NL, Cicuttini FM, Wang Y, Graves SE, et al
    No increased risk of cancer associated with metal-on-metal or ceramic-on-ceramic procedures compared to other bearing surfaces in patients with total hip arthroplasty: A nationwide linked registry cohort analysis of 167,837 patients.
    PLoS One. 2022;17:e0278241.
    >> Share

  51. NUNOMURA J, Nakano R, Naruke A, Suwabe Y, et al
    Interleukin-1beta triggers matrix metalloprotease-3 expression through p65/RelA activation in melanoma cells.
    PLoS One. 2022;17:e0278220.
    >> Share

  52. PRIMIERO CA, Finnane A, Yanes T, Peach B, et al
    Protocol to evaluate a pilot program to upskill clinicians in providing genetic testing for familial melanoma.
    PLoS One. 2022;17:e0275926.
    >> Share

  53. SCHWARTZBERG L, Broder MS, Ailawadhi S, Beltran H, et al
    Impact of early detection on cancer curability: A modified Delphi panel study.
    PLoS One. 2022;17:e0279227.
    >> Share

  54. YAZDANI Z, Biparva P, Rafiei A, Kardan M, et al
    Combination effect of cold atmospheric plasma with green synthesized zero-valent iron nanoparticles in the treatment of melanoma cancer model.
    PLoS One. 2022;17:e0279120.
    >> Share

    January 2021
  55. KHUNGER A, Piazza E, Warren S, Smith TH, et al
    CTLA-4 blockade and interferon-alpha induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
    PLoS One. 2021;16:e0245287.
    >> Share

  56. WIKSTROM JD, Lundeberg L, Frohm-Nilsson M, Girnita A, et al
    Correction: Differences in cutaneous melanoma treatment and patient satisfaction.
    PLoS One. 2021;16:e0246145.
    >> Share

  57. SUWABE Y, Nakano R, Namba S, Yachiku N, et al
    Involvement of GLUT1 and GLUT3 in the growth of canine melanoma cells.
    PLoS One. 2021;16:e0243859.
    >> Share

  58. SHAO H, Moller M, Cai L, Prokupets R, et al
    Converting melanoma-associated fibroblasts into a tumor-suppressive phenotype by increasing intracellular Notch1 pathway activity.
    PLoS One. 2021;16:e0248260.
    >> Share

  59. LEE YS, Heo W, Choi HJ, Cho HR, et al
    An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells.
    PLoS One. 2021;16:e0248870.
    >> Share

  60. LORUSSO PM, Sekulic A, Sosman JA, Liang WS, et al
    Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.
    PLoS One. 2021;16:e0248097.
    >> Share


  61. Correction: PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
    PLoS One. 2021;16:e0251020.
    >> Share

  62. RADIVOYEVITCH T, Zabor EC, Singh AD
    Uveal melanoma: Long-term survival.
    PLoS One. 2021;16:e0250939.
    >> Share

  63. ROUMEN RMH, Schuurman MS, Aarts MJ, Maaskant-Braat AJG, et al
    Survival of sentinel node biopsy versus observation in intermediate-thickness melanoma: A Dutch population-based study.
    PLoS One. 2021;16:e0252021.
    >> Share

  64. WANG X, Asami S, Kitamura D
    A novel cancer immunotherapy using tumor-infiltrating B cells in the APCmin/+ mouse model.
    PLoS One. 2021;16:e0245608.
    >> Share

  65. MATKOVIC S, Dotlic J, Gazibara T, Maric G, et al
    Functional assessment of cancer therapy questionnaire for melanoma in the Serbian population: A factor analytic approach.
    PLoS One. 2021;16:e0253937.
    >> Share

  66. KRUEGER J, Santinon F, Kazanova A, Issa ME, et al
    Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.
    PLoS One. 2021;16:e0251731.
    >> Share

  67. MINEIRO DOS SANTOS GARRETT NF, Carvalho da Costa AC, Barros Ferreira E, Damiani G, et al
    Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
    PLoS One. 2021;16:e0255716.
    >> Share

  68. PESCARMONA R, Mouton W, Walzer T, Dalle S, et al
    Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients.
    PLoS One. 2021;16:e0255972.
    >> Share

  69. SHI X, Xia S, Chu Y, Yang N, et al
    CARD11 is a prognostic biomarker and correlated with immune infiltrates in uveal melanoma.
    PLoS One. 2021;16:e0255293.
    >> Share

  70. PLOYPETCH S, Roytrakul S, Jaresitthikunchai J, Phaonakrop N, et al
    Salivary proteomics in monitoring the therapeutic response of canine oral melanoma.
    PLoS One. 2021;16:e0256167.
    >> Share

  71. ALASADY MJ, Terry AR, Pierce AD, Cavalier MC, et al
    The calcium-binding protein S100B reduces IL6 production in malignant melanoma via inhibition of RSK cellular signaling.
    PLoS One. 2021;16:e0256238.
    >> Share

  72. ZHU H, Kang M, Bai X
    TCF21 regulates miR-10a-5p/LIN28B signaling to block the proliferation and invasion of melanoma cells.
    PLoS One. 2021;16:e0255971.
    >> Share

  73. DIVINCENZO MJ, Barricklow Z, Schwarz E, Moufawad M, et al
    Loss of miR-1469 expression mediates melanoma cell migration and invasion.
    PLoS One. 2021;16:e0256629.
    >> Share

  74. GIAVINA-BIANCHI M, de Sousa RM, Paciello VZA, Vitor WG, et al
    Implementation of artificial intelligence algorithms for melanoma screening in a primary care setting.
    PLoS One. 2021;16:e0257006.
    >> Share

  75. YANG CQ, Wang H, Liu Z, Hueman MT, et al
    Integrating additional factors into the TNM staging for cutaneous melanoma by machine learning.
    PLoS One. 2021;16:e0257949.
    >> Share

  76. CHEN KJ, Li FZ, Ye Q, Jia M, et al
    HSP105 expression in cutaneous malignant melanoma: Correlation with clinicopathological characteristics.
    PLoS One. 2021;16:e0258053.
    >> Share

  77. HELMPROBST F, Kneitz S, Klotz B, Naville M, et al
    Differential expression of transposable elements in the medaka melanoma model.
    PLoS One. 2021;16:e0251713.
    >> Share

  78. CAMPOS-DO-CARMO G, Nobre AB, Cuzzi T, Argenziano G, et al
    Melanocytic lesions
    PLoS One. 2021;16:e0252162.
    >> Share

  79. SADOGHI B, Schmid-Zalaudek K, Zalaudek I, Fink-Puches R, et al
    Prevalence of nevi, atypical nevi, and lentigines in relation to tobacco smoking.
    PLoS One. 2021;16:e0254772.
    >> Share

  80. BUSS LA, Hock B, Merry TL, Ang AD, et al
    Effect of immune modulation on the skeletal muscle mitochondrial exercise response: An exploratory study in mice with cancer.
    PLoS One. 2021;16:e0258831.
    >> Share

  81. TORAL KJ, Wuenschel MA, Black EP
    Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
    PLoS One. 2021;16:e0256416.
    >> Share

  82. IKEDA Y, Wada A, Hasegawa T, Yokota M, et al
    Melanocyte progenitor cells reside in human subcutaneous adipose tissue.
    PLoS One. 2021;16:e0256622.
    >> Share

  83. MAGEE K, Marsh IR, Turek MM, Grudzinski J, et al
    Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.
    PLoS One. 2021;16:e0255798.
    >> Share

  84. BRASSARD J, Gill ME, Bernatchez E, Desjardins V, et al
    Countering the advert effects of lung cancer on the anticancer potential of dendritic cell populations reinstates sensitivity to anti-PD-1 therapy.
    PLoS One. 2021;16:e0260636.
    >> Share

  85. LELEUX JA, Albershardt TC, Reeves R, James R, et al
    Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory.
    PLoS One. 2021;16:e0259301.
    >> Share

    January 2020
  86. BOGNAR Z, Cseh AM, Fekete K, Antus C, et al
    Amiodarone's major metabolite, desethylamiodarone inhibits proliferation of B16-F10 melanoma cells and limits lung metastasis formation in an in vivo experimental model.
    PLoS One. 2020;15:e0239088.
    >> Share

  87. MENG L, He X, Zhang X, Zhang X, et al
    Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
    PLoS One. 2020;15:e0240331.
    >> Share

  88. GONG Y, Suzuki T, Kozono H, Kubo M, et al
    Tumor-infiltrating CD62L+PD-1-CD8 T cells retain proliferative potential via Bcl6 expression and replenish effector T cells within the tumor.
    PLoS One. 2020;15:e0237646.
    >> Share

  89. PORTO AC, Pinto Blumetti T, Oliveira Santos Filho IDA, Calsavara VF, et al
    Primary cutaneous melanoma of the scalp: Patterns of clinical, histological and epidemiological characteristics in Brazil.
    PLoS One. 2020;15:e0240864.
    >> Share

  90. HO JC, Lee CH, Hong CH
    Targeting steroid receptor RNA activator (SRA), a long non-coding RNA, enhances melanogenesis through activation of TRP1 and inhibition of p38 phosphorylation.
    PLoS One. 2020;15:e0237577.
    >> Share

  91. TAYLOR NJ, Gaynanova I, Eschrich SA, Welsh EA, et al
    Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment.
    PLoS One. 2020;15:e0240849.
    >> Share

  92. GUERREIRO EM, Ovstebo R, Thiede B, Costea DE, et al
    Cancer cell line-specific protein profiles in extracellular vesicles identified by proteomics.
    PLoS One. 2020;15:e0238591.
    >> Share

  93. GANBAATAR O, Konnai S, Okagawa T, Nojima Y, et al
    PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.
    PLoS One. 2020;15:e0234218.
    >> Share

  94. LUO H, Ma C
    Identification of prognostic genes in uveal melanoma microenvironment.
    PLoS One. 2020;15:e0242263.
    >> Share

  95. JUNG SK, Park YH, Shin DH, Kim HS, et al
    Visual outcomes of proton beam therapy for choroidal melanoma at a single institute in the Republic of Korea.
    PLoS One. 2020;15:e0242966.
    >> Share

  96. ZHOU S, Sakamoto K
    Citric acid promoted melanin synthesis in B16F10 mouse melanoma cells, but inhibited it in human epidermal melanocytes and HMV-II melanoma cells via the GSK3beta/beta-catenin signaling pathway.
    PLoS One. 2020;15:e0243565.
    >> Share

  97. KLOEPPING KC, Kraus AS, Hedlund DK, Gnade CM, et al
    Triphenylphosphonium derivatives disrupt metabolism and inhibit melanoma growth in vivo when delivered via a thermosensitive hydrogel.
    PLoS One. 2020;15:e0244540.
    >> Share

  98. SANGKAEW O, Phaonakrop N, Roytrakul S, Yompakdee C, et al
    Metaproteomic investigation of functional insight into special defined microbial starter on production of fermented rice with melanogenesis inhibition activity.
    PLoS One. 2020;15:e0241819.
    >> Share

  99. CULLUM RL, Lucas LM, Senfeld JI, Piazza JT, et al
    Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics.
    PLoS One. 2020;15:e0243901.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016